Uncategorized
Acucela Nominates Shintaro Asako to Its Board of Directors
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (TOKYO:4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has announced that it has nominated Shintaro Asako to stand for election to the Company’s Board of Directors (the “Board”) at the 2015 Annual Meeting of Shareholders on June 25, 2015 (the “Annual Meeting”) at Acucela’s he
